You are here
Nobivac Myxo-RHD provides active immunisation against classical strains of rabbit haemorrhagic disease (RHD) virus and myxoma virus. Both RHD and myxomatosis are widespread endemic diseases of rabbits in the United Kingdom. There is no effective treatment and both diseases are likely to prove fatal in unprotected domestic rabbits if they become infected. RHD is spread by direct contact between rabbits but also via indirect contact from contaminated environments and also via mechanical transfer from insects. Myxomatosis is commonly spread by fleas and other biting insects and but can also be transmitted by direct contact with other infected rabbits.
The vaccine is based on a recombinant attenuated myxoma vector virus which contains the RHD VP60 capsid gene such that a single vaccine virus immunises against the two diseases
Lyophilisate and solvent for suspension for injection
Each dose of reconstituted vaccine contains:
Active substance: Live myxoma vectored RHD virus strain 009: ≥103.0 and ≤106.1 FFU*
*Focus Forming Units
Indications for use
For active immunisation of rabbits from 5 weeks of age onwards to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease (RHD) caused by classical RHD virus strains.
Onset of immunity: 3 weeks.
Duration of immunity: 1 year.
Lyophilisate: Glass vial of 1 dose closed with a halogenobutyl rubber stopper and aluminium cap.
Solvent: Glass vial of 1 ml or 10 ml, or polyethylene terephthalate (PET) vial of 50 ml closed with a halogenobutyl rubber stopper and aluminium cap.
Packaging: Plastic box with 5 x 1 dose vial of vaccine and 5 x 1 ml vial of solvent.
For full information please refer to the product data sheet. Further information is available on request.
Use Medicines Responsibly. For more information please refer to the Responsible Use sections of the NOAH website.
If you are not the prescribing veterinary surgeon, advice should be sought from the medicine prescriber.
Date of preparation: January 2018